Aggressive lymphoma: Improving treatment outcome with rituximab

Anti-Cancer Drugs

Volumn 13, Issue SUPPL. 2, 2002, Pages

  Coiffier, Bertrand ^a   Pfreundschuh, Michael ^b   Stahel, Rolf ^c   Vose, Julie ^d   Zinzani, Pier L ^e  

^a HOSPICES CIVILS DE LYON   (France)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aggressive lymphoma; Immunochemotherapy; Rituximab; Salvage therapy; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; HUMAN; LYMPHOMA; MYELODYSPLASIA; NEUTROPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0036878677     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200211002-00007     Document Type: Conference Paper

References (19)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
2. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or MACOP-B. Ann Intern Med 1986; 104: 757-65.
3. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
4. Tilly H, Mounier N, Lederlin P, et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 2000; 18: 1309-15.
5. Pfreundschuh MG, Trümper L, Kloess M, et al. 2-weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. ASH 2001. Blood 2001; 98(suppl 1): 3027.
6. Pfreundschuh MG, Trümper L, Kloess M, et al. CHOEP (CHOP + etoposide): the new standard regimen for younger patients with low risk (low LDH) aggressive non-Hodgkin's lymphoma (NHL). ASH 2001. Blood 2001; 98(suppl 1): 3026.
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
8. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-32.
9. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
10. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-97.
11. Coiffier B, Lepage E, Herbrecht R, et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomised GELA trial. Blood 2000; 96: 950.
12. Coiffier B, Fermé C, Hermine O, et al. Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma. An update of the GELA study. Blood 2001; 98(suppl 1): 3025.
13. Coiffier B, Lepage E, Macro M, et al. Updated results of the GELA randomised trial comparing rituximab plus CHOP (R-CHOP) to CHOP in elderly patients with diffuse large B-cell lymphoma (DLCL). Hematol J 2001; 1(suppl 1): 194.
14. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-86.
15. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61: 5137-44.
16. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001; 97: 1392-8.
17. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-82.
18. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633-42.
19. Jost LM, Jermann MA, Stahel RA, et al. Rituximab-EPOCH - an effective salvage therapy for relapsed, refractory, or transformed B-cell lymphomas. Results of a phase II study. Proceedings of the American Society for Clinical Oncology (ASCO), 2001 San Francisco, California. Abstract 1157.